Published in Nat Rev Drug Discov on February 01, 2005
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov (2010) 7.48
Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev (2008) 4.80
Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater (2009) 4.77
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol (2011) 4.22
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev (2013) 3.44
Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol (2009) 2.99
The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater (2011) 2.84
Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano (2008) 2.76
Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74
Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater (2011) 2.71
"SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem (2006) 2.58
A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci U S A (2006) 2.55
Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J (2007) 2.38
Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev (2010) 2.37
Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A (2011) 2.27
In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood (2010) 2.17
Sheddable coatings for long-circulating nanoparticles. Pharm Res (2007) 2.15
Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol (2015) 2.08
A novel intracellular protein delivery platform based on single-protein nanocapsules. Nat Nanotechnol (2009) 1.94
Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed Engl (2011) 1.93
Delivery of multiple siRNAs using lipid-coated PLGA nanoparticles for treatment of prostate cancer. Nano Lett (2011) 1.92
Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano (2012) 1.86
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85
Tumour-targeted nanomedicines: principles and practice. Br J Cancer (2008) 1.81
Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov (2011) 1.78
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release (2009) 1.76
Multilayered polyelectrolyte assemblies as platforms for the delivery of DNA and other nucleic acid-based therapeutics. Adv Drug Deliv Rev (2008) 1.74
Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst (2009) 1.73
Shear-stress sensitive lenticular vesicles for targeted drug delivery. Nat Nanotechnol (2012) 1.70
Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci U S A (2009) 1.63
A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci Signal (2014) 1.63
Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano (2012) 1.62
Long-circulating liposomes radiolabeled with [18F]fluorodipalmitin ([18F]FDP). Nucl Med Biol (2007) 1.60
Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system. J Control Release (2009) 1.60
Coating optimization of superparamagnetic iron oxide nanoparticles for high T2 relaxivity. Nano Lett (2010) 1.58
Delivery of therapeutic proteins. J Pharm Sci (2010) 1.58
Nanotechnology in medical imaging: probe design and applications. Arterioscler Thromb Vasc Biol (2008) 1.55
Gold nanoparticle platforms as drug and biomacromolecule delivery systems. J Control Release (2010) 1.54
Self-assembling materials for therapeutic delivery. Acta Biomater (2008) 1.51
Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today (2009) 1.47
State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release (2014) 1.46
Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res (2011) 1.45
Oxidation-triggered release of fluorescent molecules or drugs from mesoporous Si microparticles. ACS Nano (2008) 1.44
Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc Chem Res (2009) 1.42
Top-down particle fabrication: control of size and shape for diagnostic imaging and drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.40
Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater (2012) 1.40
Supramolecular nanostructures formed by anticancer drug assembly. J Am Chem Soc (2013) 1.40
Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging. Bioconjug Chem (2008) 1.37
Monolayer coated gold nanoparticles for delivery applications. Adv Drug Deliv Rev (2011) 1.36
A supramolecular approach for preparation of size-controlled nanoparticles. Angew Chem Int Ed Engl (2009) 1.35
On the near-wall accumulation of injectable particles in the microcirculation: smaller is not better. Sci Rep (2013) 1.35
Lipid modification of proteins through sortase-catalyzed transpeptidation. J Am Chem Soc (2008) 1.34
Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med (Maywood) (2008) 1.33
Selective filtering of particles by the extracellular matrix: an electrostatic bandpass. Biophys J (2009) 1.32
Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release (2014) 1.32
A fluorescence-based technique to construct size distributions from single-object measurements: application to the extrusion of lipid vesicles. Biophys J (2008) 1.31
Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther (2008) 1.30
Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nat Rev Clin Oncol (2010) 1.30
Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics (2014) 1.29
Liposomes as nanomedical devices. Int J Nanomedicine (2015) 1.29
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm (2010) 1.28
Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials (2013) 1.26
Biomimetic delivery with micro- and nanoparticles. Adv Mater (2012) 1.25
The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials (2012) 1.25
Peptide-based Biopolymers in Biomedicine and Biotechnology. Mater Sci Eng R Rep (2008) 1.25
Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release (2011) 1.25
Polymeric nanomedicine for cancer MR imaging and drug delivery. Chem Commun (Camb) (2009) 1.24
Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta (2010) 1.23
Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications. Curr Pharm Des (2010) 1.23
Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br J Cancer (2008) 1.23
Externally controlled on-demand release of anti-HIV drug using magneto-electric nanoparticles as carriers. Nat Commun (2013) 1.23
Size matters: gold nanoparticles in targeted cancer drug delivery. Ther Deliv (2012) 1.22
Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine (2014) 1.22
Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine (2012) 1.21
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) (2013) 1.21
Genome-free viral capsids as multivalent carriers for taxol delivery. Angew Chem Int Ed Engl (2009) 1.21
Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist (2012) 1.20
"Clickable" polymer-caged nanobins as a modular drug delivery platform. J Am Chem Soc (2009) 1.18
The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents. Biomaterials (2009) 1.17
Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur J Nucl Med Mol Imaging (2006) 1.17
Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci (2013) 1.16
Hybrid nanoparticles for detection and treatment of cancer. Adv Mater (2012) 1.16
Labeling of Polymer Nanostructures for Medical Imaging: Importance of crosslinking extent, spacer length, and charge density. Macromolecules (2007) 1.15
Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur J Pharm Sci (2007) 1.14
Controllable microfluidic synthesis of multiphase drug-carrying lipospheres for site-targeted therapy. Biotechnol Prog (2009) 1.14
Spectrally tunable leakage-free gold nanocontainers. J Am Chem Soc (2009) 1.14
Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer. Open Nanomed J (2011) 1.14
Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer. Colloids Surf B Biointerfaces (2011) 1.14
Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv (2010) 1.13
Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol Pharm (2011) 1.11
Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO J (2007) 1.11
Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy. Nat Commun (2014) 1.11
Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev (2011) 1.11
Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev (2013) 1.11
Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol (2010) 1.11
Activation of latent HIV using drug-loaded nanoparticles. PLoS One (2011) 1.10
Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum Vaccin Immunother (2013) 1.10
Stimuli-responsive liposome fusion mediated by gold nanoparticles. ACS Nano (2010) 1.10